Skip to main content
logo
Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price on Sep 15, 2025

Revenue by Product

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Novel Antibody-based Therapeutic Products
85.19M
Log In
Log In
Log In
Log In
Novel Antibody-based Therapeutic Products Growth
1.03%
Log In
Log In
Log In
Log In

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
United States
65.98M
Log In
Log In
Log In
Log In
United States Growth
-2.70%
Log In
Log In
Log In
Log In
Eastern Asia
7.46M
Log In
Log In
Log In
Log In
Latin America
4.72M
Log In
Log In
Log In
Log In
Western Asia
4.05M
Log In
Log In
Log In
Log In
Western Europe
2.09M
Log In
Log In
Log In
Log In
Other Regions
890.00K
Log In
Log In
Log In
Log In
Other Regions Growth
-94.61%
Log In
Log In
Log In
Log In